Form 4: UNH CFO Wayne DeVeydt Receives Equity Grant

UnitedHealth Group's CFO, Wayne S. DeVeydt, was granted 8,855 restricted stock units and 35,517 non-qualified stock options, vesting annually from 2027 to 2030.

Summary

• Wayne S. DeVeydt, Chief Financial Officer of UnitedHealth Group Inc. (UNH), reported an acquisition of equity securities.
• The transaction occurred on February 23, 2026, under a Rule 10b5-1 plan.
• DeVeydt acquired 8,855 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $282.34 per share.
• These RSUs will vest at a rate of 25% annually on February 23 from 2027 through 2030.
• Additionally, DeVeydt acquired 35,517 non-qualified stock options with an exercise price of $282.34.
• These stock options will also vest at a rate of 25% annually on February 23 from 2027 through 2030 and expire on February 23, 2036.
• Following these transactions, DeVeydt beneficially owns 19,516.941 shares of Common Stock and 35,517 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates continued executive alignment with shareholder interests through long-term equity incentives, which is a standard and healthy practice for corporate governance.

Positives

• The grant of restricted stock units and stock options aligns the CFO's interests with long-term shareholder value.
• The significant number of options (35,517) and RSUs (8,855) represents a substantial compensation package, indicating confidence in the executive.
• The multi-year vesting schedule encourages sustained performance and retention of key management.

Negatives

• The equity grants are subject to a multi-year vesting schedule, meaning the full benefit is not immediately realized.
• The stock options have an exercise price equal to the grant price, meaning they only gain value if the stock price increases above $282.34.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive equity grants are a standard practice in the healthcare industry, aligning management incentives with long-term company performance and shareholder interests. This type of compensation package is common for senior executives in large-cap healthcare providers like UnitedHealth Group.

Stakeholder Impact

• Shareholders: The equity grant aligns the CFO's financial interests with long-term shareholder value, potentially encouraging decisions that benefit the stock price over time.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting employee morale.

Next Steps

• The restricted stock units will vest at a rate of 25% annually on February 23 from 2027 through 2030.
• The non-qualified stock options will vest at a rate of 25% annually on February 23 from 2027 through 2030.
• The non-qualified stock options will expire on February 23, 2036.

Key Dates

Recommendation

While the equity grant to the CFO is a positive sign of executive alignment and retention, a Form 4 filing detailing a compensation grant is generally not a standalone catalyst for a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for investors who believe in the company's long-term strategy and management stability, as it indicates standard executive compensation practices are in place.

Keywords

UnitedHealth Group, UNH, Wayne S. DeVeydt, CFO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Beneficial Ownership